KUALA LUMPUR, Malaysia, July 15, 2015 /PRNewswire/ --
Scientists from the Department of Medicine at the University of Malaysia have recently presented the very latest data from a study on colorectal cancer screening using the M2-PK stool test in the renowned publication PLOS ONE. These latest results for the M2-PK test from the cancer specialist Professor Khean-Lee Goh - one of the most renowned experts in Asia on this subject - and his colleagues confirm once again the exceptionally high capability and accuracy of the M2-PK test for colorectal cancer screening.
Professor Goh investigated the enyzme biomarker M2-PK in a patient group with 100 colorectal cancer cases and a population-based control group of 200 healthy people. The M2-PK test detected 93% of colorectal cancers. Furthermore, it recognized 97.5% of the control group as truly healthy. The positive predictive value for colorectal cancer was 94.9% and the predictive value to exclude colorectal cancer (negative predictive value) was 96.5%. The overall accuracy of the M2-PK test was 96%.
The investigators also made two additional important findings. Firstly, the M2-PK test has a very high detection rate (sensitivity) for right-sided (85.7%) as well as for left-sided colorectal cancers (94.2%). This result is especially important because right-sided colorectal cancers are more often missed than left-sided with conventional screening methods.
Secondly, M2-PK had almost the same very high rate of detection (sensitivity) across all four tumour stages (stage 1 = 94.1%; stage 2 = 88.9%; stage 3 = 96.4%; stage 4 = 90.3%).
The M2-PK rapid stool test is available for the doctors' practice as ScheBo®• M2-PK QuickTM (ScheBo• Biotech AG).
Source: K.-L. Goh, et al.: http://dx.doi.org/10.1371/journal.pone.0131616
ScheBo• Biotech AG / Tel: +49-(0)641-4996-0 / Fax: +49-(0)641-4996-78 http://www.schebo.com
SOURCE ScheBo Biotech AG